These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

410 related items for PubMed ID: 21498163

  • 21. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail].
    Lin TY, Zhang HY, Huang Y, Guan ZZ, Shen T, Shi YK, Zhu J, Ke XY, Wang HQ, Shen ZX, Yu SY, Liu T, Shi XL.
    Ai Zheng; 2005 Dec; 24(12):1421-6. PubMed ID: 16351785
    [Abstract] [Full Text] [Related]

  • 22. Results of CHOP chemotherapy for diffuse large B-cell lymphoma.
    Hallack Neto AE, Pereira J, Beitler B, Chamone DA, Llacer PD, Dulley FL, Macedo MC, Chaoubah A.
    Braz J Med Biol Res; 2006 Oct; 39(10):1315-22. PubMed ID: 16906323
    [Abstract] [Full Text] [Related]

  • 23. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.
    Park YH, Lee JJ, Ryu MH, Kim SY, Kim DH, Do YR, Lee KH, Oh SJ, Kim YK, Suh CW, Heo DS, Ryoo BY, Kim JK, Song HS, Lee WS, Kim HJ, Bang YJ, Yang SH, Sohn SK, Kang YK, Lymphoma Study Division of the Korean Cancer Study Group.
    Ann Hematol; 2006 Apr; 85(4):257-62. PubMed ID: 16416337
    [Abstract] [Full Text] [Related]

  • 24. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
    Gobbi PG, Ghirardelli ML, Avanzini P, Baldini L, Quarta G, Stelitano C, Broglia C, Loni C, Silingardi V, Ascari E.
    Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
    [Abstract] [Full Text] [Related]

  • 25. Combined therapy in the treatment of primary mediastinal B-cell lymphoma: conventional versus escalated chemotherapy.
    Avilés A, García EL, Fernández R, Gonzalez JL, Neri N, Díaz-Maqueo JC.
    Ann Hematol; 2002 Jul; 81(7):368-73. PubMed ID: 12185505
    [Abstract] [Full Text] [Related]

  • 26. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
    Pfreundschuh M, Ho AD, Cavallin-Stahl E, Wolf M, Pettengell R, Vasova I, Belch A, Walewski J, Zinzani PL, Mingrone W, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Corrado C, Scheliga A, Loeffler M, Kuhnt E, MabThera International Trial (MInT) Group.
    Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558
    [Abstract] [Full Text] [Related]

  • 27. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis.
    Shah NN, Szabo A, Huntington SF, Epperla N, Reddy N, Ganguly S, Vose J, Obiozor C, Faruqi F, Kovach AE, Costa LJ, Xavier AC, Okal R, Kanate AS, Ghosh N, Kharfan-Dabaja MA, Strelec L, Hamadani M, Fenske TS, Calzada O, Cohen JB, Chavez J, Svoboda J.
    Br J Haematol; 2018 Feb; 180(4):534-544. PubMed ID: 29265182
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience.
    Savage KJ, Al-Rajhi N, Voss N, Paltiel C, Klasa R, Gascoyne RD, Connors JM.
    Ann Oncol; 2006 Jan; 17(1):123-30. PubMed ID: 16236753
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study.
    Miller TP, Dahlberg S, Weick JK, Files JC, Eyre HJ, Pendergrass KB, Fisher RI.
    J Clin Oncol; 1990 Dec; 8(12):1951-8. PubMed ID: 1700079
    [Abstract] [Full Text] [Related]

  • 34. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
    Wu HJ, Zhang QY, Chen DF, Guan XJ, Zhang BL, Ma J.
    Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
    [Abstract] [Full Text] [Related]

  • 35. Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.
    Rigacci L, Carrai V, Nassi L, Alterini R, Longo G, Bernardi F, Bosi A.
    Cancer; 2005 Mar 01; 103(5):970-7. PubMed ID: 15666323
    [Abstract] [Full Text] [Related]

  • 36. Real world experience of R-CHOP with or without consolidative radiotherapy vs DA-EPOCH-R in the first-line treatment of primary mediastinal B-cell lymphoma.
    Chan EHL, Koh LP, Lee J, De Mel S, Jeyasekharan A, Liu X, Tang T, Lim ST, Tao M, Quek R, Farid Bin Harunal Ras M, Lee YS, Diong C, Tan D, Kim SJ, Chee YL, Poon LMM.
    Cancer Med; 2019 Aug 01; 8(10):4626-4632. PubMed ID: 31264808
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial.
    Hüttmann A, Rekowski J, Müller SP, Hertenstein B, Franzius C, Mesters R, Weckesser M, Kroschinsky F, Kotzerke J, Ganser A, Bengel FM, La Rosée P, Freesmeyer M, Höffkes HG, Hertel A, Behringer D, Prange-Krex G, Griesshammer M, Holzinger J, Wilop S, Krohn T, Raghavachar A, Maschmeyer G, Brink I, Schroers R, Gaska T, Bernhard H, Giagounidis A, Schütte J, Dienst A, Hautzel H, Naumann R, Klein A, Hahn D, Pöpperl G, Grube M, Marienhagen J, Schwarzer A, Kurch L, Höhler T, Steiniger H, Nückel H, Südhoff T, Römer W, Brinkmann M, Ose C, Alashkar F, Schmitz C, Dürig J, Hoelzer D, Jöckel KH, Klapper W, Dührsen U.
    Ann Hematol; 2019 Apr 01; 98(4):897-907. PubMed ID: 30610279
    [Abstract] [Full Text] [Related]

  • 40. CHOP vs. ProMACE-CytaBOM in the treatment of aggressive non-Hodgkin's lymphomas: long-term results of a multicenter randomized trial.(PETHEMA: Spanish Cooperative Group for the Study of Hematological Malignancies Treatment, Spanish Society of Hematology).
    Montserrat E, García-Conde J, Viñolas N, López-Guillermo A, Hernández-Nieto L, Zubizarreta A, Maldonado J, Alcalá A, Faura MV, Llorente A, Bladé J, Fontanillas M, Estapé J.
    Eur J Haematol; 1996 Nov 01; 57(5):377-83. PubMed ID: 9003479
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.